(Q46006540)

18 December 2017

title

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. (English)

1 reference

18 December 2017

0 references

0 references

1 reference

3

1 reference

18 December 2017

author name string

B A Fijal

1

1 reference

18 December 2017

B J Kinon

2

1 reference

18 December 2017

V L Stauffer

4

1 reference

18 December 2017

R R Conley

5

1 reference

18 December 2017

H H Jamal

6

1 reference

18 December 2017

J M Kane

7

1 reference

18 December 2017

M M Witte

8

1 reference

18 December 2017

J P Houston

9

1 reference

18 December 2017

publication date

19 May 2009

1 reference

18 December 2017

The Pharmacogenomics Journal

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

18 December 2017

volume

9

1 reference

18 December 2017

issue

5

1 reference

18 December 2017

page(s)

311-318

1 reference

18 December 2017

https://scigraph.springernature.com/pub.10.1038/tpj.2009.24

exact match

0 references

cites work

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Remission in schizophrenia: proposed criteria and rationale for consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

A highly significant association between a COMT haplotype and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Early Prediction of Antipsychotic Response in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.24

21 January 2018

Identifiers

DOI

10.1038/TPJ.2009.24

1 reference

18 December 2017

Dimensions Publication ID

1016116840

0 references

1 reference

18 December 2017